Seattle Genetics, Daiichi Sankyo strike licensing deal

07/9/2008 |

Seattle Genetics has entered into a licensing agreement with Daiichi Sankyo Co. Ltd. for its "antibody drug conjugate" technology. The deal entitles the biotech firm to an upfront payment of $4 million and allows the Japanese drugmaker to use the technique to target an antigen found on various forms of solid tumors.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT